VAIM Successfully Hosts New Product juveàcell Launching Symposium

VAIM Successfully Hosts New Product juveàcell Launching Symposium

VAIM, a leading aesthetic medical device company, announced on the 20th that it successfully held juveàcell Launching Symposium 2025 on November 16 at Walkerhill Hotel in Seoul, with more than 200 physicians from across Korea in attendance. The event marked the official Korea-only launch of juveàcell.

Held under VAIM’s vision of Self-Directed Aesthetics, the symposium served as a platform to introduce the new product, juveàcell, to the medical field and to share real clinical experiences and procedural insights among practitioners.

The new product has drawn significant attention as an innovative hADM filler designed to promote both restoration and regeneration of skin function. It is developed using human acellular dermal matrix safely decellularized through a supercritical process, a technology proven in the field of medical reconstruction.

juveàcell is a prefilled syringe product based on hADM (Human Acellular Dermal Matrix) technology used in reconstructive medicine. As a biocompatible, tissue-derived biomaterial, it demonstrates clinical potential in areas such as skin soothing and elasticity improvement. Through a supercritical CO₂ decellularization method, immunogenic components are removed while essential ECM structures—including collagen and elastin—are preserved to the greatest extent. This structural stability allows juveàcell to focus not only on volume supplementation but also on restoring the skin’s healthy biological function.

A VAIM representative stated, “juveàcell is expected to become a turning point in the widespread adoption of hADM fillers. Unlike conventional fillers, its function-restoration-based approach and ready-to-use design will provide physicians with a safer and more predictable treatment environment.”

Introduction of VAIM
Founded in 2014, VAIM is a global medical aesthetics company that develops human tissue regeneration products and improved pharmaceuticals by utilizing its accumulated technology and know-how in biocompatible and biodegradable polymers. It has developed and patented a PDLLA-based manufacturing technology that reduces the risk of nodule formation compared to other ingredient structures, and in 2019, its subsidiary, VAIM, entered the skin booster market with JUVELOOK, which utilizes this technology. JUVELOOK is a collagen booster that induces the production of ECM (collagen, elastin) to provide direct remodeling effects on the skin such as elasticity and wrinkle improvement, and is divided into JUVELOOK and LENISNA depending on the purpose. After quickly proving its safety and effectiveness since its launch, VAIM currently has product export contracts with 72 countries.